The trial, sponsored by Yonsei University, investigates the use of autologous BM-MSCs for treating alcoholic liver cirrhosis, a significant unmet medical need given the rising prevalence of liver diseases globally. If successful, this therapy could position itself in a niche market with limited competition, particularly in the context of regenerative medicine for liver conditions. The commercial potential is underscored by the increasing focus on cell-based therapies and the growing demand for innovative treatments in hepatology. Diligence should focus on regulatory pathways, potential reimbursement scenarios, and the scalability of BM-MSC production.